Acorda Therapeutics (ACOR) Rating Reiterated by JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their hold rating on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research report report published on Tuesday morning.

A number of other research firms have also weighed in on ACOR. Zacks Investment Research lowered Acorda Therapeutics from a hold rating to a strong sell rating in a research report on Monday, October 30th. Janney Montgomery Scott set a $17.00 price objective on Acorda Therapeutics and gave the company a hold rating in a research report on Thursday, November 16th. HC Wainwright set a $34.00 price objective on Acorda Therapeutics and gave the company a buy rating in a research report on Thursday, December 14th. Stifel Nicolaus lowered Acorda Therapeutics from a buy rating to a hold rating and reduced their price objective for the company from $26.00 to $15.00 in a research report on Thursday, November 16th. Finally, Cowen reaffirmed a buy rating and set a $30.00 price objective on shares of Acorda Therapeutics in a research report on Friday, November 17th. Four analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Acorda Therapeutics has an average rating of Hold and a consensus price target of $21.35.

Shares of Acorda Therapeutics (ACOR) traded up $1.05 during trading hours on Tuesday, hitting $24.30. The stock had a trading volume of 457,962 shares, compared to its average volume of 574,540. Acorda Therapeutics has a 12-month low of $13.60 and a 12-month high of $33.00. The company has a market cap of $1,140.00, a price-to-earnings ratio of -20.08 and a beta of 1.58. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.77 and a quick ratio of 2.40.

Acorda Therapeutics (NASDAQ:ACOR) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by ($0.26). Acorda Therapeutics had a negative return on equity of 8.18% and a negative net margin of 10.25%. The firm had revenue of $141.07 million during the quarter, compared to the consensus estimate of $150.64 million. During the same period in the prior year, the company posted ($0.04) EPS. The firm’s revenue was up 4.0% on a year-over-year basis. analysts forecast that Acorda Therapeutics will post -0.13 earnings per share for the current fiscal year.

In other Acorda Therapeutics news, insider Burkhard Blank sold 11,050 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.53, for a total transaction of $226,856.50. Following the sale, the insider now directly owns 33,150 shares in the company, valued at approximately $680,569.50. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 7.90% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. GSA Capital Partners LLP purchased a new stake in Acorda Therapeutics during the 3rd quarter valued at $541,000. Convergence Investment Partners LLC purchased a new position in shares of Acorda Therapeutics in the 3rd quarter worth $1,294,000. OxFORD Asset Management LLP purchased a new position in shares of Acorda Therapeutics in the 3rd quarter worth $2,025,000. KBC Group NV boosted its stake in shares of Acorda Therapeutics by 194.3% in the 3rd quarter. KBC Group NV now owns 64,007 shares of the biopharmaceutical company’s stock worth $1,514,000 after buying an additional 42,256 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Acorda Therapeutics by 11.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,655,959 shares of the biopharmaceutical company’s stock worth $62,813,000 after buying an additional 283,091 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2018/01/10/acorda-therapeutics-acor-rating-reiterated-by-jpmorgan-chase-co.html.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

Analyst Recommendations for Acorda Therapeutics (NASDAQ:ACOR)

What are top analysts saying about Acorda Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acorda Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit